Compass, Inc. Share Price Target ‘$4.15’, now -4.2% Downside Potential

DirectorsTalk Interviews

Compass, Inc. which can be found using ticker (COMP) have now 9 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The target price High/Low ranges between $6.00 and $3.00 calculating the mean target share price we have $4.15. (at the time of writing). Given that the stocks previous close was at $4.33 this would imply there is a potential downside of -4.2%. It’s also worth noting that there is a 50 day moving average of $3.56 while the 200 day moving average is $3.18. The market cap for the company is 2.13B. The stock price for Affirm Holdings, Inc. is $4.30 USD

The potential market cap would be $2,037,923,773 based on the market consensus.

The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of $10.46 and a -10.37% return on assets.

Compass, Inc. is a technology-enabled brokerage that provides an end-to-end platform of software, services, and support to helps its residential real estate agents to deliver service to seller and buyer clients. The Company’s platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service, brokerage services and other critical functionalities, all custom-built for the real estate industry and enables its core brokerage services. The platform also uses data, analytics, artificial intelligence and machine learning to deliver recommendations and outcomes for Compass agents and their clients. Agents use its platform to assist home sellers and buyers in listing, marketing, selling and finding homes, as well as through the provision of services, such as title, escrow and mortgage. Its Glide tools include completion of various real estate forms, offers preparation, as well as e-signature and collaboration capabilities.

Share on:

Latest Company News

AIM admission marks new phase for EDX Medical’s diagnostic expansion

EDX Medical has joined AIM as it advances the commercial rollout of diagnostic tests targeting cancer and other major diseases, supported by growing clinical screening programmes.

QinetiQ strengthens maritime test positioning as uncrewed naval systems scale

QinetiQ’s expanded underwater testing capacity strengthens its role in the growing market for uncrewed maritime defence systems.

Zotefoams update strengthens the investment case

Zotefoams’ latest update shows a stronger, broader growth business than the current valuation appears to recognise.

Commercial milestones could define Quadrise’s next investment phase

Commercial agreements, project execution and customer adoption remain the key markers investors are likely to watch as Quadrise moves further towards commercial deployment.

Natural hydrogen opens a new investment front in South Australia

Investor interest in natural hydrogen is building as South Australia becomes an early proving ground for exploration, testing and potential commercial development.

Touchstone advances Trinidad output strategy as new wells support cash flow

Touchstone Exploration has brought two Trinidad oil wells into production while advancing gas infrastructure work aimed at improving cash flow, pricing and operational reliability.

    Search